A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French sarcoma group

Annals of Oncology

Volumn 24, Issue 4, 2013, Pages 1099-1104

  Pautier, P ^a   Floquet, A ^b   Gladieff, L ^c   Bompas, E ^d   Ray Coquard, I ^e   Piperno Neumann, S ^f   Selle, F ^g   Guillemet, C ^h   Weber, B ⁱ   Largillier, R ^j   Bertucci, F ^k   Opinel, P ^l   Duffaud, F ^m   Reynaud Bougnoux, A ⁿ   Delcambre, C ^o   Isambert, N ^p   Kerbrat, P ^q   Netter pinon, G ^r   Pinto, N ^s   Duvillard, P ^a   Haie Meder, C ^a   Lhomme C ^a   Rey, A ^a   more..

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSTITUT BERGONIÉ   (France)

^c INSTITUT CLAUDIUS REGAUD   (France)

^d CENTRE RENÉ GAUDUCHEAU   (France)

^e CENTRE LÉON BÉRARD   (France)

^f INSTITUT CURIE   (France)

^g HÔPITAL TENON   (France)

^h CENTRE HENRI BECQUEREL   (France)

ⁱ CENTRE ALEXIS VAUTRIN   (France)

^j CENTRE ANTOINE LACASSAGNE   (France)

^k INSTITUT PAOLI CALMETTES   (France)

^l CENTRE HOSPITALIER DU PAYS D AIX   (France)

^m TIMONE HOSPITAL   (France)

ⁿ CHU BRETONNEAU   (France)

^o CENTRE FRANÇOIS BACLESSE   (France)

^p CENTRE GEORGES FRANÇOIS LECLERC   (France)

^q CENTRE EUGÈNE MARQUIS   (France)

^r CENTRE HOSPITALIER DE MEAUX   (France)

^s Department of Radiotherapy   (France)

more..

Author keywords

Adjuvant; Chemotherapy; Sarcoma; Treatment; Uterine

Indexed keywords

CISPLATIN; DOXORUBICIN; IFOSFAMIDE; MESNA; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; ARTICLE; BLADDER DISEASE; BRACHYTHERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CARCINOSARCOMA; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG FATALITY; ENCEPHALITIS; EXTERNAL BEAM RADIOTHERAPY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK; THROMBOCYTOPENIA; UTERUS SARCOMA;

EID: 84875617583     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds545     Document Type: Article

References (27)

1. Reed NS, Mangioni C, Malmström H et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 2008; 44: 808-818.
2. Pautier P, Genestie C, Rey A et al. Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma. Cancer 2000; 88: 1425-1431.
3. Omura GA, Blessing JA, Major F et al. A randomized clinical trial of adjuvant adriamycine in uterine sarcomas: a Gynecologic Oncologic Group study. J Clin Oncol 1985; 3:1240.-1245.
4. Pautier P, Rey A, Haie-Meder C et al. Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy in localized uterine sarcomas: results of a case-control study with radiotherapy alone. Int J Gynecol Cancer 2004; 14: 1112-1117.
5. Salazar OM, Bonfiglio TA, Patten SF et al. Uterine sarcomas: natural history, treatment and prognosis. Cancer 1978; 42: 1152-1160.
6. Kaplan ES, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-461.
7. Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet 1997; 350: 1647-1654.
8. Pervaiz N, Colterjohn N, Farrokhyar F et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008; 113: 73-81.
9. Italiano A, Delva F, Mathoulin-Pelissier S et al. Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database. Ann Oncol 2010; 21: 2436-2441.
10. Omura GA, Major FJ, Blessing JA et al. A randomized study of adriamycin with and without dimethyl triazinoimidazole carboxamide in advanced uterine sarcomas. Cancer 1983; 52: 626-632.
11. Gershenson DM, Kavanagh JJ, Copeland LJ et al. High-dose doxorubicin infusion therapy for disseminated mixed mesodermal sarcoma of the uterus. Cancer 1987; 59: 1264-1267.
12. Sutton G, Blessing J, Barrett R et al. Phase II trial of ifosfamide and mesna in leimyosarcoma of the uterus: a Gynecologic Oncologic Group study. Am J Obstet Gynecol 1992; 166: 556-559.
13. Sutton GP, Blessing JA, Rosenheim N et al. Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus. Am J Obstet Gynecol 1989; 161: 309-312.
14. Thigpen JT, Blessing JA, Beecham J et al. Phase II trial of cisplatin as first line chemotherapy in patients with advanced or recurrent uterine sarcomas (a Gynecologic Oncologic Group study). J Clin Oncol 1991; 9: 1962-1966.
15. Thigpen JT, Blessing JA, Orr JW, Jr et al. Phase II trial of cisplatin in treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncologic Group study. Cancer Treat Rep 1986; 70: 271-274.
16. Piver MS, Deeulis TG, Lele SB et al. Cyclophosphamide, vincristine, adriamycine, and dimethyl-triazeno imidazole carboxamide (CYVADIC) for sarcomas of the female genital tract. Gynecol Oncol 1982; 14: 319-323.
17. Sutton G, Blessing JA, Malfetano JH. Ifosfamide and doxorubicine in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group Study. Gynecol Oncol 1996; 2: 226-229.
18. Muss HB, Bundy B, disaia PJ et al. Treatment of recurrent or advanced uterine sarcoma: a randomized trial of doxorubicine versus doxorubicine and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group). Cancer 1985; 55: 1648-1653.
19. Hensley ML, Maki R, Venkatraman E et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002; 20: 2824-2831.
20. Pautier P, Genestie C, Fizazi K et al. Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas. Int J Gynecol Cancer 2002; 12: 749-754.
21. Le Cesne A, Antoine E, Spielmann M et al. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995; 13: 1600-1608.
22. Van Glabbeke M, van Oosterom AT, Oosterhuis JW et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens-an European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 1999; 17: 150-157.
23. Hempling RE, Piver MS, Baker TR. Impact on progression-free survival of adjuvant cyclophosphamide, vincristine, doxorubicin (Adriamycine), and dacarbazine (CYVADIC) chemotherapy for stage I uterine sarcoma. Am J Clin Oncol 1995; 18: 282-286.
24. Buchsbaum HJ, Lifshitz S, Blythe JG. Prophylactic chemotherapy in stages I and II uterine sarcoma. Gynecol Oncol 1979; 8: 346-348.
25. Hannigan EV, Freedman RS, Rutledge FN. Adjuvant chemotherapy in early uterine sarcoma. Gynecol Oncol 1983; 15: 56-64.
26. Van Nagell JR, Hanson MB, Donaldson ES et al. Adjuvant vincristine, dactinomycin, and cyclophosphamide in stage I uterine sarcomas: a pilot study. Cancer 1986; 57: 1451-1454.
27. Hensley ML, Ishill N, Soslow R et al. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: results of a prospective study. Gynecol Oncol 2009; 112: 563-567.